The  	The  	 DT	O
role  	role  	 NN	O
of  	of  	 IN	O
i.v.  	i.v.  	 CD	B-NP
ibandronate  	ibandronate  	 JJ	O
administration  	administration  	 NN	O
in  	in  	 IN	O
osteoporosis  	osteoporosis  	 JJ	B-NP
therapy  	therapy  	 NN	I-NP
Osteoporosis  	Osteoporosis  	 NNP	I-NP
is  	is  	 VBZ	O
a  	a  	 DT	O
chronic  	chronic  	 JJ	B-NP
disease  	disease  	 NN	I-NP
of  	of  	 IN	I-NP
the  	the  	 DT	I-NP
osseous  	osseous  	 JJ	I-NP
system  	system  	 NN	I-NP
characterised  	characterised  	 NN	O
by  	by  	 IN	O
decreased  	decreased  	 JJ	O
strength  	strength  	 NN	O
of  	of  	 IN	O
bone  	bone  	 NN	O
tissue 	tissue 	 NN	O
,  	,  	 ,	O
which  	which  	 WDT	O
in  	in  	 IN	O
turn  	turn  	 NN	O
leads  	leads  	 VBZ	O
to  	to  	 TO	O
increased  	increased  	 VB	B-NP
fracture  	fracture  	 JJ	I-NP
risk 	risk 	 NN	I-NP
.  	.  	 .	O
It  	It  	 PRP	O
has  	has  	 VBZ	O
been  	been  	 VBN	O
demonstrated  	demonstrated  	 VBN	O
that  	that  	 IN	O
osteoporosis  	osteoporosis  	 NN	B-NP
affects  	affects  	 VBZ	O
more  	more  	 JJR	O
than  	than  	 IN	O
30 	30 	 CD	O
%  	%  	 NN	O
of  	of  	 IN	O
women  	women  	 NNS	O
after  	after  	 IN	O
the  	the  	 DT	O
menopause  	menopause  	 NN	O
( 	( 	 -LRB-	O
World  	World  	 NNP	O
Health  	Health  	 NNP	O
Organization 	Organization 	 NNP	O
,  	,  	 ,	O
1994 	1994 	 CD	O
) 	) 	 -RRB-	O
.  	.  	 .	O
However 	However 	 RB	O
,  	,  	 ,	O
the  	the  	 DT	O
disease  	disease  	 NN	O
is  	is  	 VBZ	O
also  	also  	 RB	O
observed  	observed  	 VBN	O
in  	in  	 IN	O
men 	men 	 NNS	O
.  	.  	 .	O
The  	The  	 DT	O
primary  	primary  	 JJ	B-NP
goals  	goals  	 NNS	I-NP
of  	of  	 IN	I-NP
osteoporosis  	osteoporosis  	 JJ	I-NP
therapy  	therapy  	 NN	I-NP
include  	include  	 VBP	O
prevention  	prevention  	 VBN	O
of  	of  	 IN	O
low-energy  	low-energy  	 JJ	B-NP
fractures  	fractures  	 NN	I-NP
and  	and  	 CC	O
general  	general  	 JJ	O
improvement  	improvement  	 NN	O
of  	of  	 IN	O
quality  	quality  	 NN	O
of  	of  	 IN	O
life 	life 	 NN	O
.  	.  	 .	O
Any  	Any  	 DT	O
patient  	patient  	 NN	O
with  	with  	 IN	O
diagnosed  	diagnosed  	 JJ	O
osteoporosis  	osteoporosis  	 NN	B-NP
requires 	requires 	 VBZ	O
,  	,  	 ,	O
besides  	besides  	 IN	O
prevention 	prevention 	 NN	O
,  	,  	 ,	O
the  	the  	 DT	O
application  	application  	 NN	O
of  	of  	 IN	O
proper  	proper  	 JJ	O
treatment 	treatment 	 NN	O
.  	.  	 .	O
Of  	Of  	 IN	O
the  	the  	 DT	O
available  	available  	 JJ	O
therapeutic  	therapeutic  	 JJ	B-NP
options 	options 	 NNS	I-NP
,  	,  	 ,	O
the  	the  	 DT	O
best  	best  	 JJS	O
are  	are  	 VBP	O
bisphosphonates 	bisphosphonates 	 VBN	O
,  	,  	 ,	O
medical  	medical  	 JJ	B-NP
agents  	agents  	 NNS	I-NP
with  	with  	 IN	O
well  	well  	 RB	O
identified  	identified  	 VBN	B-NP
properties 	properties 	 NNS	I-NP
,  	,  	 ,	O
therapeutic  	therapeutic  	 JJ	B-NP
efficacy 	efficacy 	 NN	I-NP
,  	,  	 ,	O
and  	and  	 CC	O
safety  	safety  	 NN	O
which  	which  	 WDT	O
has  	has  	 VBZ	O
been  	been  	 VBN	O
confirmed  	confirmed  	 VBN	O
in  	in  	 IN	O
many  	many  	 JJ	O
clinical  	clinical  	 JJ	B-NP
studies 	studies 	 NNS	I-NP
.  	.  	 .	O
Therefore 	Therefore 	 RB	O
,  	,  	 ,	O
they  	they  	 PRP	O
are  	are  	 VBP	O
recommended  	recommended  	 VBN	O
as  	as  	 IN	O
first  	first  	 JJ	O
line  	line  	 NN	B-NP
drugs  	drugs  	 NNS	I-NP
for  	for  	 IN	I-NP
osteoporosis 	osteoporosis 	 NN	I-NP
.  	.  	 .	O
The  	The  	 DT	O
efficacy  	efficacy  	 NN	O
of  	of  	 IN	O
oral  	oral  	 JJ	B-NP
preparations  	preparations  	 NNS	I-NP
may  	may  	 MD	O
be  	be  	 VB	O
limited 	limited 	 VBN	O
,  	,  	 ,	O
due  	due  	 JJ	O
to  	to  	 TO	O
low  	low  	 JJ	O
bioavailability 	bioavailability 	 NN	B-NP
,  	,  	 ,	O
complications  	complications  	 NNS	B-NP
and  	and  	 CC	O
adverse  	adverse  	 JJ	O
effects  	effects  	 NNS	O
from  	from  	 IN	O
the  	the  	 DT	O
gastrointestinal  	gastrointestinal  	 JJ	B-NP
tract 	tract 	 NN	I-NP
.  	.  	 .	O
So  	So  	 IN	O
the  	the  	 DT	O
parenteral  	parenteral  	 JJ	B-NP
administration  	administration  	 NN	I-NP
of  	of  	 IN	I-NP
bisphosphonates  	bisphosphonates  	 NN	I-NP
is  	is  	 VBZ	O
a  	a  	 DT	O
valuable  	valuable  	 JJ	O
alternative 	alternative 	 NN	O
.  	.  	 .	O
A  	A  	 DT	O
fine  	fine  	 JJ	B-NP
example  	example  	 NN	I-NP
of  	of  	 IN	O
such  	such  	 JJ	O
therapy  	therapy  	 NN	O
is  	is  	 VBZ	O
the  	the  	 DT	O
intravenous  	intravenous  	 JJ	B-NP
administration  	administration  	 NN	I-NP
of  	of  	 IN	I-NP
ibandronate 	ibandronate 	 NN	I-NP
.  	.  	 .	O
Short  	Short  	 JJ	O
injection  	injection  	 NN	O
time  	time  	 NN	O
periods  	periods  	 NNS	O
and  	and  	 CC	O
the  	the  	 DT	O
relatively  	relatively  	 RB	O
long 	long 	 RB	O
,  	,  	 ,	O
three-month  	three-month  	 JJ	B-NP
intervals  	intervals  	 NNS	I-NP
between  	between  	 IN	O
administrations  	administrations  	 NNS	B-NP
are  	are  	 VBP	O
unquestionable  	unquestionable  	 JJ	O
advantages  	advantages  	 NNS	O
of  	of  	 IN	O
this  	this  	 DT	O
therapy  	therapy  	 NN	B-NP
mode 	mode 	 NN	I-NP
.  	.  	 .	O
In  	In  	 IN	O
addition 	addition 	 NN	B-NP
,  	,  	 ,	O
the  	the  	 DT	O
therapy  	therapy  	 NN	O
does  	does  	 VBZ	O
not  	not  	 RB	O
constrain  	constrain  	 VB	O
a  	a  	 DT	O
patient 	patient 	 NN	O
's  	's  	 POS	O
everyday  	everyday  	 JJ	O
activity 	activity 	 NN	O
,  	,  	 ,	O
and  	and  	 CC	O
simultaneously  	simultaneously  	 RB	O
provides  	provides  	 VBZ	O
regular  	regular  	 JJ	B-NP
contact  	contact  	 NN	I-NP
with  	with  	 IN	O
doctors  	doctors  	 NNS	O
and  	and  	 CC	O
the  	the  	 DT	O
therapeutic  	therapeutic  	 JJ	B-NP
centre 	centre 	 NN	I-NP
.  	.  	 .	O
Additionally 	Additionally 	 RB	O
,  	,  	 ,	O
a  	a  	 DT	O
good  	good  	 JJ	O
tolerance  	tolerance  	 NN	O
of  	of  	 IN	O
the  	the  	 DT	O
drug  	drug  	 NN	O
and  	and  	 CC	O
its  	its  	 PRP$	O
high  	high  	 JJ	O
therapeutic  	therapeutic  	 JJ	B-NP
efficacy 	efficacy 	 NN	I-NP
,  	,  	 ,	O
proven  	proven  	 VBN	O
by  	by  	 IN	O
appreciably  	appreciably  	 RB	O
reduced  	reduced  	 VBN	B-NP
fracture  	fracture  	 JJ	I-NP
risks 	risks 	 NNS	I-NP
,  	,  	 ,	O
significantly  	significantly  	 RB	O
improves  	improves  	 VBZ	O
the  	the  	 DT	O
quality  	quality  	 NN	O
of  	of  	 IN	O
life  	life  	 NN	O
of  	of  	 IN	O
patients  	patients  	 NNS	O
suffering  	suffering  	 VBG	O
from  	from  	 IN	O
osteoporosis 	osteoporosis 	 NN	B-NP
.  	.  	 .	O
This  	This  	 DT	O
paper  	paper  	 NN	O
is  	is  	 VBZ	O
a  	a  	 DT	O
thorough  	thorough  	 JJ	O
review  	review  	 NN	O
of  	of  	 IN	O
current  	current  	 JJ	O
knowledge  	knowledge  	 NN	O
on  	on  	 IN	O
the  	the  	 DT	O
efficacy  	efficacy  	 NN	O
and  	and  	 CC	O
safety  	safety  	 NN	O
of  	of  	 IN	O
i.v.  	i.v.  	 CD	B-NP
ibandronate  	ibandronate  	 NN	O
in  	in  	 IN	O
osteoporosis  	osteoporosis  	 JJ	B-NP
therapy 	therapy 	 NN	I-NP
,  	,  	 ,	O
as  	as  	 RB	O
presented  	presented  	 VBN	O
in  	in  	 IN	O
the  	the  	 DT	O
latest  	latest  	 JJS	O
literature  	literature  	 NN	B-NP
reports 	reports 	 NNS	I-NP
.  	.  	 .	O
